Oxetorone: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
| width = 180 | | width = 180 | ||
| alt = Ball-and-stick model | | alt = Ball-and-stick model | ||
| image2 = Oxetorone-3D-balls.png | | image2 = 360px-Oxetorone-3D-balls.png | ||
| alt2 = Ball-and-stick model | | alt2 = Ball-and-stick model | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 46: | Line 46: | ||
| smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34 | | smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34 | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Oxetorone''' ([[International Nonproprietary Name|INN]]), as '''oxetorone fumarate''' ([[United States Adopted Name|USAN]]) (brand names '''Nocertone''', '''Oxedix'''), is a [[serotonin antagonist]], [[antihistamine]], and [[alpha blocker]] used as an [[antimigraine drug]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1493|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1493–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA131|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="BoxtelSantoso2008">{{cite book|author1=C.J. van Boxtel|author2=B. Santoso|author3=I.R. Edwards|title=Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition|url=http://books.google.com/books?id=idbvAgAAQBAJ&pg=PA699|date=6 August 2008|publisher=IOS Press|isbn=978-1-60750-345-3|pages=699–}}</ref><ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref> | '''Oxetorone''' ([[International Nonproprietary Name|INN]]), as '''oxetorone fumarate''' ([[United States Adopted Name|USAN]]) (brand names '''Nocertone''', '''Oxedix'''), is a [[serotonin antagonist]], [[antihistamine]], and [[alpha blocker]] used as an [[antimigraine drug]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1493|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1493–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA131|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="BoxtelSantoso2008">{{cite book|author1=C.J. van Boxtel|author2=B. Santoso|author3=I.R. Edwards|title=Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition|url=http://books.google.com/books?id=idbvAgAAQBAJ&pg=PA699|date=6 August 2008|publisher=IOS Press|isbn=978-1-60750-345-3|pages=699–}}</ref><ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref> | ||
| Line 56: | Line 60: | ||
{{Antimigraine preparations}} | {{Antimigraine preparations}} | ||
[[Category:Alpha blockers]] | [[Category:Alpha blockers]] | ||
[[Category:Antimigraine drugs]] | [[Category:Antimigraine drugs]] | ||
[[Category:H1 receptor antagonists]] | [[Category:H1 receptor antagonists]] | ||
[[Category:Heterocyclic compounds (3 rings)]] | [[Category:Heterocyclic compounds (3 rings)]] | ||
[[Category: | [[Category:Drug]] | ||
Revision as of 19:44, 15 April 2015
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C21H21NO2 |
| Molar mass | 319.40 g/mol |
| 3D model (JSmol) | |
| |
| (verify) | |
|
WikiDoc Resources for Oxetorone |
|
Articles |
|---|
|
Most recent articles on Oxetorone |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Oxetorone at Clinical Trials.gov Clinical Trials on Oxetorone at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Oxetorone
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Oxetorone Discussion groups on Oxetorone Directions to Hospitals Treating Oxetorone Risk calculators and risk factors for Oxetorone
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Oxetorone |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxetorone (INN), as oxetorone fumarate (USAN) (brand names Nocertone, Oxedix), is a serotonin antagonist, antihistamine, and alpha blocker used as an antimigraine drug.[1][2][3][4]
Association with hyperprolactinemia has been described.[5]
References
- ↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1493–. ISBN 978-0-412-46630-4.
- ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- ↑ C.J. van Boxtel; B. Santoso; I.R. Edwards (6 August 2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition. IOS Press. pp. 699–. ISBN 978-1-60750-345-3.
- ↑ Massiou H (2000). "[Prophylactic treatments of migraine]". Rev. Neurol. (Paris) (in French). 156 Suppl 4: 4S79–86. PMID 11139754.
- ↑ Pradalier A (December 1996). "Hyperprolactinaemia and depression induced by oxetorone". Cephalalgia. 16 (8): 560–1. doi:10.1046/j.1468-2982.1996.1608560.x. PMID 8980859.
Categories:
- Pages with script errors
- CS1 maint: Unrecognized language
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Alpha blockers
- Antimigraine drugs
- H1 receptor antagonists
- Heterocyclic compounds (3 rings)
- Drug